The role of endothelin-1 in human hypertension

被引:1
作者
Shreenivas, Satya
Oparil, Suzanne
机构
[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA
[2] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Endothelin-1 (ET-1) is a powerful vasoconstrictor and mitogen that contributes to blood pressure elevation and related vascular remodeling and target organ damage. ET-1 also influences salt and water homeostasis through effects on the renin-angiotensin-aldosterone system and vasopressin, thus elevating blood pressure and increasing vascular tone. Circulating ET-1 levels are elevated in a variety of animal models of hypertension, particularly those that are salt-dependent, and in a subset of human hypertensives, i.e. African-Americans and those with renal dysfunction. ET type B receptors, which normally have vasodilator functions, mediate vasoconstriction in some hypertensives, and hypertensive African-American patients may have increased numbers of vasoconstrictor ET-B receptors in their vascular smooth muscle. Whether selective ET-A or combined ET-A/ET-B receptor antagonists are more efficacious in treating hypertension and related cardiovascular disease is controversial. ET antagonists have only modest BP lowering effects in the general population of essential hypertensives, but show promise in patients with severe, treatment resistant hypertension.
引用
收藏
页码:157 / 178
页数:22
相关论文
共 114 条
[91]   Inhibition of myocardial endothelin pathway improves long-term survival in heart failure [J].
Sakai, S ;
Miyauchi, T ;
Kobayashi, M ;
Yamaguchi, I ;
Goto, K ;
Sugishita, Y .
NATURE, 1996, 384 (6607) :353-355
[92]   Vascular endothelin in hypertension [J].
Schiffrin, EL .
VASCULAR PHARMACOLOGY, 2005, 43 (01) :19-29
[93]   Role of endothelin-1 in hypertension [J].
Schiffrin, EL .
HYPERTENSION, 1999, 34 (04) :876-881
[94]   Systemic and renal effects of an ETA receptor subtype-specific antagonist in healthy subjects [J].
Schmetterer, L ;
Dallinger, S ;
Bobr, B ;
Selenko, N ;
Eichler, HG ;
Wolzt, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (05) :930-934
[95]   CYTOTOXIC EFFECT OF ENDOTHELIN-1 DURING SIMULATED ISCHEMIA IN CULTURED RAT MYOCYTES [J].
STAWSKI, G ;
OLSEN, UB ;
GRANDE, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 201 (01) :123-124
[96]   Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men [J].
Strachan, FE ;
Spratt, JC ;
Wilkinson, IB ;
Johnston, NR ;
Gray, GA ;
Webb, DJ .
HYPERTENSION, 1999, 33 (01) :581-585
[97]   Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans [J].
Sutsch, G ;
Bertel, O ;
Kiowski, W .
CARDIOVASCULAR DRUGS AND THERAPY, 1997, 10 (06) :717-725
[98]   PLASMA-CONCENTRATIONS OF ENDOTHELIN-1 IN SPONTANEOUSLY HYPERTENSIVE RATS AND DOCA-SALT HYPERTENSIVE RATS [J].
SUZUKI, N ;
MIYAUCHI, T ;
TOMOBE, Y ;
MATSUMOTO, H ;
GOTO, K ;
MASAKI, T ;
FUJINO, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 167 (03) :941-947
[99]  
Treinen KA, 1999, TERATOLOGY, V59, P51, DOI 10.1002/(SICI)1096-9926(199901)59:1<51::AID-TERA10>3.0.CO
[100]  
2-I